Intrathecal (L6-S1) or intravesical administration of a PAC1 receptor antagonist, PACAP(6-38), increased bladder capacity but not intravesical pressure with CYP-induced cystitis (Braas et al., 2006). Here, ADCYAP1 is linked to cystitis.